What changed: HER2-positive breast cancer
Every dated change on the records linked to HER2-positive breast cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Approval2Trial result1Milestone20This record1
September 2026 · 1
2026 · 2
2025 · 1
2024 · 2
2021 · 2
2020 · 1
2019 · 1
2018 · 1
2017 · 1
2015 · 1
2013 · 2
2012 · 1
2007 · 1
2005 · 1
2001 · 1
1998 · 3
- 1998ApprovalCapecitabineCapecitabine approved in US
Metastatic breast cancer after anthracycline and taxane; later adjuvant and metastatic colorectal cancer, rectal chemoradiotherapy
- 1998MilestoneHER2-positive breast cancerTrastuzumab approved
A milestone in how this cancer is treated.
- 1998MilestoneHER2-positive breast cancerTrastuzumab approved for metastatic disease
First antibody for a solid tumour; OS benefit with chemotherapy.
1987 · 2
- 1987MilestoneHER2-positive breast cancerSlamon shows HER2 amplification marks aggressive disease, and a drug target
A milestone in how this cancer is treated.
- 1987MilestoneHER2Slamon shows HER2 amplification marks aggressive disease, and a drug target
Science paper identifying HER2/neu amplification in 25-30% of breast cancers.